

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. A recent study published in *The New England Journal of Medicine* and subsequently updated at ASCO 2016 demonstrated that patients with mCRC and _____ responded to treatment with the immune checkpoint inhibitor pembrolizumab.
 - a. Microsatellite stable tumors
 - b. MSI-H tumors
 - c. Both a and b
 - d. Neither a nor b
2. In a study for patients with BRAF V600E mutation-positive mCRC, the triplet combination of the BRAF inhibitor dabrafenib, the MEK inhibitor trametinib and the anti-EGFR antibody panitumumab demonstrated improved and promising activity compared to the doublet combination of panitumumab with either dabrafenib or trametinib.
 - a. True
 - b. False
3. Interim results of the Phase II CheckMate 142 study presented at ASCO 2016 evaluating nivolumab with or without ipilimumab for patients with mCRC with or without high microsatellite instability demonstrated encouraging clinical activity in patients with MSI-H mCRC with nivolumab alone and in combination with ipilimumab.
 - a. True
 - b. False
4. Which of the following is the mechanism of action of TAS-102?
 - a. Anti-angiogenic
 - b. Antibody-drug conjugate
 - c. Anti-PD-1 antibody
 - d. Oral nucleoside
5. Approximately what proportion of patients with GC have HER2-amplified disease?
 - a. 5% to 20%
 - b. 35% to 50%
 - c. >50%
6. Results of a Phase Ib study presented at ASCO 2016 evaluating the cancer stemness inhibitor napabucasin (BBI608) in combination with FOLFIRI with or without bevacizumab for mCRC demonstrated that napabucasin _____ be safely combined with FOLFIRI with or without bevacizumab.
 - a. Could
 - b. Could not
7. Side effects typically associated with TAS-102 therapy include which of the following?
 - a. Hepatic dysfunction
 - b. Neutropenia
 - c. Rash
 - d. Renal dysfunction
 - e. Vomiting
 - f. All of the above
8. The Phase III BRIGHTER trial is evaluating _____ with weekly paclitaxel versus placebo with weekly paclitaxel for previously treated gastric or GEJ adenocarcinoma.
 - a. Napabucasin
 - b. Nivolumab
 - c. Regorafenib
 - d. TAS-102
9. Side effects which may be associated with ramucirumab include _____.
 - a. Hypertension
 - b. Nosebleeds
 - c. Bowel perforation
 - d. Thromboembolism
 - e. All of the above
10. Approximately what proportion of patients with squamous cell carcinoma of the esophagus exhibit PD-L1 expression?
 - a. 10%
 - b. 25%
 - c. 50%
 - d. 100%